document
updat
guidelin
publish
includ
scientif
public
may
provid
evidencebas
recommend
common
manag
question
occur
routin
clinic
practic
manag
adult
patient
lrti
topic
includ
manag
outsid
hospit
manag
insid
hospit
includ
communityacquir
pneumonia
cap
acut
exacerb
copd
aecopd
acut
exacerb
bronchiectasi
prevent
background
section
grade
evid
tabl
also
includ
target
audienc
guidelin
thu
whose
routin
practic
includ
manag
adult
lrti
european
respiratori
societi
er
collabor
european
societi
clinic
microbiolog
infecti
diseas
escmid
publish
guidelin
manag
lower
respiratori
tract
infect
lrti
adult
document
base
publish
scientif
literatur
end
updat
guidelin
includ
public
may
taskforc
respons
guidelin
develop
sponsor
er
escmid
member
taskforc
member
sponsor
er
andor
escmid
object
provid
evidencebas
recommend
common
manag
question
occur
routin
clinic
practic
manag
adult
patient
lrti
target
audienc
guidelin
thu
whose
routin
practic
includ
manag
adult
lrti
document
begin
definit
background
section
microbi
caus
resist
pharmacokineticspharmacodynam
convent
referenc
guidelin
section
captur
manag
outsid
hospit
manag
insid
hospit
includ
communityacquir
pneumonia
cap
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
acut
exacerb
bronchiectasi
prevent
guidelin
manag
infect
mean
condit
aecopd
aspect
manag
unrel
infect
eg
use
steroid
bronchodil
includ
contain
grade
recommend
also
background
inform
recommend
detail
new
cite
refer
evid
grade
updat
origin
data
public
usual
repeat
reader
refer
origin
public
updat
use
methodolog
layout
document
includ
text
recommend
evid
tabl
use
search
filter
document
describ
detail
previou
public
websit
documentshttp
wwwersnetorg
http
wwwescmid
org
identifi
relev
manuscript
pubm
publish
juli
may
therebi
retriev
titl
load
electron
databas
titl
identifi
potenti
relev
public
expert
panel
member
process
evid
apprais
grade
appendix
recommend
develop
grade
appendix
document
use
document
take
clinic
question
recommend
guidelin
present
new
inform
avail
follow
new
recommend
circumst
lack
new
evid
sometim
even
presenc
new
evid
recommend
unchang
case
indic
part
guidelin
new
question
recommend
ad
cover
relev
area
includ
guidelin
eg
aspir
pneumonia
guidelin
use
guid
manag
adult
lower
respiratori
tract
infect
lrti
seen
follow
text
diagnosi
clinic
syndrom
within
group
difficult
identifi
accur
absenc
agre
definit
syndrom
guidelin
use
opinion
clinician
lrti
syndrom
present
follow
put
forward
definit
guid
clinician
seen
ensu
text
label
alway
inaccur
definit
pragmat
base
synthesi
avail
studi
primarili
meant
simpl
appli
clinic
practic
might
expens
scientif
accuraci
definit
mutual
exclus
lower
respiratori
tract
infect
umbrella
term
includ
other
also
use
case
classifi
one
group
new
evid
identifi
would
lead
chang
clinic
definit
therefor
unchang
public
sinc
public
guidelin
term
health
careassoci
pneumonia
hcap
put
forward
captur
group
patient
pneumonia
acquir
outsid
hospit
expect
caus
similar
pathogen
differ
usual
found
communityacquir
lrti
opinion
taskforc
member
evid
base
support
use
term
clinic
relev
europ
present
time
hcap
therefor
cover
document
acut
ill
present
day
less
usual
cough
main
symptom
least
one
lower
respiratori
tract
symptom
sputum
product
dyspnoea
wheez
chest
discomfortpain
altern
explan
eg
sinus
asthma
definit
communityacquir
pneumonia
cap
support
chest
radiograph
find
lung
shadow
like
new
elderli
presenc
chest
radiograph
shadow
accompani
acut
clinic
ill
unspecifi
without
obviou
caus
event
natur
cours
diseas
character
worsen
patient
baselin
dyspnoea
cough
andor
sputum
beyond
daytoday
variabl
suffici
warrant
chang
manag
chest
radiograph
shadow
consist
infect
present
patient
consid
cap
patient
featur
suggest
bronchiectasi
event
natur
cours
diseas
character
worsen
patient
baselin
dyspnoea
andor
cough
andor
sputum
beyond
daytoday
variabl
suffici
warrant
chang
manag
chest
radiograph
shadow
consist
infect
present
patient
consid
cap
new
inform
avail
microbiolog
caus
lrti
wide
variat
studi
regard
frequenc
microorgan
explain
sever
factor
includ
differ
studi
popul
eg
age
rang
risk
factor
geograph
area
studi
sampl
microbiolog
method
exampl
studi
focus
bacteri
agent
other
virus
intracellular
bacteria
supplement
tradit
diagnost
method
new
technologybas
method
could
achiev
higher
microbi
yield
major
studi
lrti
larg
proport
case
pathogen
identifi
either
appropri
test
perform
usual
rule
outpati
organ
miss
age
year
renal
cardiac
comorbid
ill
non
alveolar
infiltr
independ
associ
higher
proport
unknown
aetiolog
patient
hospit
cap
hand
multipl
organ
may
found
adult
alreadi
describ
youngster
paediatr
studi
found
polymicrobi
infect
cap
dual
viral
infect
present
dual
bacteri
infect
mix
viralbacteri
infect
hospit
adult
nonimmunocompromis
patient
polymicrobi
cap
occur
gutierrez
et
al
report
two
pathogen
age
well
inpati
outpati
frequent
combin
bacteria
atyp
organ
two
bacteria
patient
mix
pneumonia
like
comorbid
alter
outcom
angel
marco
et
al
found
frequent
copathogen
pneumonia
c
pneumonia
frequent
combin
pneumonia
either
influenza
parainfluenza
viru
influenza
viru
c
pneumonia
de
roux
et
al
report
patient
mix
cap
pneumonia
preval
microorgan
frequent
combin
pneumonia
h
influenza
influenza
viru
pneumonia
frequent
associ
mix
pyogen
pneumonia
group
among
patient
mix
infect
song
et
al
found
patient
two
differ
pathogen
three
differ
pathogen
four
differ
pathogen
frequent
combin
pneumonia
c
pneumonia
mix
infect
found
patient
pneumococc
cap
jen
et
al
found
polymicrobi
infect
involv
bacteri
viral
pathogen
occur
patient
cap
might
associ
sever
pneumonia
johansson
et
al
found
two
pathogen
patient
cap
determin
aetiolog
commonli
pneumonia
togeth
respiratori
viru
evid
concurr
bacteri
infect
found
lung
tissu
specimen
us
patient
fatal
case
confirm
pandem
influenza
includ
caus
pneumonia
tabl
summar
microbiolog
aetiolog
lrti
commun
studi
investig
microbiolog
caus
cap
outpati
tabl
patient
admit
hospit
tabl
intens
care
unit
tabl
studi
mild
infect
suggest
microbi
aetiolog
outpati
similar
hospit
patient
commun
regular
ward
extracellular
bacteria
especi
streptococcu
pneumonia
pneumonia
first
place
follow
haemophilu
influenza
h
influenza
staphylococcu
aureu
aureu
moraxella
catarrhali
among
intracellular
bacilli
mycoplasma
pneumonia
pneumonia
common
follow
frequenc
legionella
chlamydia
speci
virus
involv
communityacquir
lrti
cap
intens
care
unit
aureu
gramneg
bacilli
legionella
spp
might
frequent
encount
recurr
cap
like
gramneg
bacteria
involv
less
like
legionella
spp
involv
origin
nosocomi
pathogen
methicillinresist
aureu
mrsa
dissemin
last
decad
commun
communityacquir
mrsa
camrsa
methicillin
resist
mediat
meca
gene
associ
pantonvalentin
leukocidin
pvl
toxin
creat
lytic
pore
cell
membran
neutrophil
induc
releas
neutrophil
chemotact
factor
promot
inflamm
tissu
destruct
new
pvlposit
clone
may
aris
dissemin
commun
mrsa
emerg
infecti
agent
increas
frequenc
associ
skin
softtissu
infect
commun
set
howev
camrsa
also
lead
sever
pulmonari
infect
includ
necrot
haemorrhag
pneumonia
pneumothorax
pneumopyothorax
empyema
ventilatori
failur
septicaemia
coxiella
burnetii
gramneg
intracellular
bacterium
potenti
bioterror
agent
respons
q
fever
may
wide
varieti
clinic
manifest
includ
flulik
syndrom
pneumonia
longlast
fatigu
syndrom
c
burnetii
present
worldwid
cattl
sheep
goat
common
reservoir
q
fever
occur
endem
case
outbreak
endem
area
outbreak
ocur
europ
recent
decad
includ
switzerland
spain
uk
germani
recent
netherland
repeatedli
sinc
notifi
case
import
virus
causal
agent
confirm
lrti
cap
major
aetiolog
cap
studi
look
virus
bacteria
virus
common
aetiolog
agent
pneumonia
sporad
viral
pneumonia
occur
recent
year
due
new
viru
avian
influenza
viru
hantaviru
coronaviru
avian
influenza
viru
infect
increas
risk
pandem
much
sever
routin
season
influenza
associ
sever
ill
mortal
rate
especi
peopl
age
year
hantaviru
pulmonari
syndrom
recogn
retrospect
identifi
use
serolog
test
patient
similar
ill
syndrom
result
sever
hantavirus
sin
nombr
viru
avoid
area
infect
rodent
live
prevent
measur
outbreak
sever
acut
respiratori
syndrom
sar
report
mainli
asian
countri
canada
new
virus
belong
coronavirida
famili
found
respons
spring
outbreak
sever
pneumonia
report
conjunct
concurr
isol
novel
swineorigin
influenza
subtyp
virus
rare
predomin
sinc
pandem
featur
epidem
similar
past
influenza
pandem
new
influenza
viru
affect
younger
popul
suggest
rel
protect
person
expos
strain
childhood
pandem
sever
pneumonia
report
conjunct
novel
influenza
subtyp
viru
pneumonia
due
viru
superinfect
pneumonia
staphylococcu
microorgan
isol
hospit
elderli
patient
cap
shown
tabl
larg
variat
depend
elderli
threshold
patient
live
comorbid
howev
gutierez
et
al
found
age
strong
influenc
incid
cap
caus
main
microbi
pathogen
age
associ
higher
risk
acquir
pneumonia
pneumonia
influenza
viru
chlamydia
speci
ingarfield
et
al
emphas
enterobacteriaca
account
isol
patient
older
year
tabl
provid
microbiolog
aetiolog
airway
infect
patient
copd
exacerb
found
studi
use
variou
method
recent
studi
microbiolog
acut
exacerb
chronic
bronchiti
found
influenc
baselin
level
lung
function
pathogen
typic
atyp
bacteria
andor
viru
found
respiratori
secret
sampl
p
aeruginosa
suspect
patient
treat
antibiot
vaccin
influenza
shortterm
colon
follow
clearanc
longterm
persist
p
aeruginosa
observ
serum
antibodi
respons
mediat
clearanc
p
aeruginosa
mucoid
strain
persist
airway
microbiolog
pattern
airway
infect
may
also
differ
pneumon
nonpneumon
hospit
exacerb
copd
shown
prospect
studi
patient
identif
pathogen
frequent
pneumon
case
vs
pneumonia
virus
frequent
vs
respect
respiratori
virus
frequent
found
induc
sputum
hospit
patient
copd
exacerb
control
stabl
copd
subject
vs
frequent
virus
rhinoviru
influenza
parainfuenza
rsv
howev
exacerb
chronic
bronchiti
andor
copd
may
due
viral
andor
bacteri
infect
infect
may
occur
without
exacerb
final
bacteri
exacerb
copd
could
relat
appear
new
strain
pneumonia
h
influenza
catarrhali
colon
airway
studi
assess
microbiolog
pattern
airway
colon
bronchiectasi
studi
investig
microbiolog
aetiolog
exacerb
main
result
steadi
state
bronchiectasi
provid
tabl
highlight
high
frequenc
pseudomona
infect
particularli
case
impair
lung
function
prospect
studi
patient
clinic
stabl
bronchiectasi
multivari
analysi
found
earli
diagnosi
diseas
year
age
reduc
fev
predict
varicosecyst
bronchiectasi
risk
factor
bronchial
colon
pathogen
bacteria
mainli
h
influenza
p
aeruginosa
odd
ratio
respect
studi
patient
steadyst
bronchiectasi
presenc
p
aeruginosa
sputum
associ
lower
fev
fvc
ratio
vs
absenc
pathogen
microorgan
higher
volum
daili
sputum
product
score
vs
studi
fev
fvc
high
sputum
output
independ
associ
increas
risk
sputum
isol
p
aeruginosa
odd
ratio
respect
major
chang
caus
pathogen
lrti
inform
avail
frequenc
polymicrobi
infect
includ
viral
infect
pvlproduc
staphylococcu
aureu
emerg
new
caus
often
sever
cap
current
remain
uncommon
inform
avail
frequenc
antimicrobi
resist
set
streptococcu
pneumonia
betalactam
preval
resist
penicillin
drug
among
pneumococci
consider
complic
empir
treatment
respiratori
tract
infect
worryingli
major
resist
isol
resist
multipl
class
antimicrobi
seriou
impact
mani
firstlin
antimicrobi
therapi
mechan
resist
penicillin
blactam
due
alter
penicillinbind
protein
pbp
pbp
interact
blactam
enzymat
form
coval
complex
via
activesit
serin
loss
affin
pbp
affect
blactam
although
may
vari
substanti
depend
drug
affin
given
blactam
differ
differ
pbp
convers
one
pbp
distinct
affin
differ
blactam
therefor
point
mutat
reduc
affin
one
blactam
necessarili
affect
affin
anoth
compound
howev
nation
committe
clinic
laboratori
standard
nccl
guidelin
state
pneumococc
isol
suscept
penicillin
consid
suscept
blactam
gener
accept
mic
amoxicillin
extendedspectrum
cephalosporin
usual
equal
two
four
time
lower
mic
benzylpenicillin
howev
pneumococci
resist
amoxicillin
extendedspectrum
cephalosporin
mic
agent
equal
dilut
higher
mic
penicillin
identifi
pneumococci
decreas
suscept
penicillin
much
higher
rate
resist
class
antibiot
mention
carbapenem
imipenem
meropenem
ertapenem
activ
blactam
avail
prsp
among
parenter
cephalosporin
good
activ
cefotaxim
ceftriaxon
cefepim
cefpirom
import
note
parenter
thirdgener
cephalosporin
consider
less
activ
exampl
ceftizoxim
ceftazidim
latter
link
poor
clinic
respons
amoxicillin
remain
activ
oral
blactam
among
cephalosporin
cefditoren
cefpodoxim
activ
cefuroxim
cefprozil
use
cefuroxim
case
bacteraem
pneumococc
pneumonia
caus
penicillin
nonsuscept
strain
link
increas
mortal
preval
penicillinresist
streptococcu
pneumonia
prsp
multidrugresist
sp
vari
region
data
preval
antibiot
resist
among
streptococcu
pneumonia
regularli
produc
earss
project
europeanwid
network
nation
surveil
system
provid
refer
data
antimicrobi
resist
public
health
purpos
network
receiv
fund
european
commiss
http
wwwearssrivmnl
invas
pneumonia
isol
report
countri
nonsuscept
penicillin
fig
penicillin
nonsuscept
pneumonia
pnsp
show
heterogen
pictur
europ
northern
european
countri
level
nonsuscept
finland
n
ireland
n
report
rel
high
level
high
level
pnsp
mainli
report
southern
eastern
europ
cypru
n
franc
n
hungari
n
malta
n
turkey
n
level
penicillin
nonsuscept
fin
land
ireland
risen
significantli
two
countri
highest
level
pnsp
franc
israel
show
signific
decreas
rate
pnsp
past
year
lithuania
norway
latter
significantli
laboratori
report
consist
last
year
also
show
decreas
trend
pnsp
belgium
proport
pnsp
well
prsp
continu
decreas
significantli
croatia
hungari
ireland
turkey
signific
increas
also
observ
percentag
fulli
resist
isol
see
fig
chang
distribut
serotyp
compar
small
serogroup
still
preval
one
wherea
serogroup
serogroup
becam
slightli
preval
serogroup
becam
less
preval
popul
highest
resist
proport
identifi
serogroup
includ
sevenconjug
vaccin
anoth
recent
survey
interest
perform
eastern
southern
mediterranean
countri
period
arm
project
collect
suscept
test
result
invas
isol
pneumonia
blood
spinal
fluid
cultur
routin
process
within
particip
laboratori
situat
algeria
cypru
egypt
jordan
lebanon
malta
morocco
tunisia
turkey
overal
isol
report
nonsuscept
penicillin
highest
proport
report
algeria
lebanon
us
incid
invas
pneumococc
diseas
due
penicillinresist
isol
increas
p
penicillinresist
isol
belong
rapidli
emerg
clonal
complex
relat
multidrugresist
taiwan
import
find
high
level
penicillin
resist
among
strain
serotyp
amoxicillin
mic
mgl
cefotaxim
mic
mgl
frequent
multiresist
preclud
use
oral
blactam
treatment
infect
caus
resist
strain
special
concern
increas
european
countri
mdr
strain
serotyp
particularli
spain
franc
new
suscept
breakpoint
pneumonia
publish
clinic
laboratori
standard
institut
clsi
januari
result
reevalu
show
clinic
respons
penicillin
preserv
clinic
studi
pneumococc
infect
despit
reduc
suscept
respons
vitro
antimicrobi
suscept
breakpoint
current
establish
base
pharmacokinet
pharmacodynam
properti
antimicrobi
agent
ii
data
correl
individu
mic
result
patient
outcom
former
criteria
suscept
intermedi
resist
mic
breakpoint
penicillin
mgl
respect
pneumococc
isol
regardless
clinic
syndrom
rout
penicillin
administr
breakpoint
remain
unchang
patient
without
mening
treat
oral
penicillin
eg
outpati
pneumonia
patient
without
mening
treat
intraven
penicillin
new
breakpoint
mgl
respect
chang
penicillin
breakpoint
pneumonia
potenti
allow
clinician
increas
use
penicillin
treat
penicillinsuscept
nonmening
pneumococc
infect
instead
use
broaderspectrum
antimicrobi
use
encourag
prevent
spread
antimicrobialresist
pneumonia
also
spread
methicillinresist
staphylococcu
aureu
clostridium
difficil
result
use
broaderspectrum
antimicrobi
accord
penicillin
breakpoint
dose
suitabl
blactam
agent
treatment
hospit
patient
pneumonia
streptococcu
pneumonia
suspect
penicillin
g
g
mu
iv
h
adequ
strain
penicillin
mic
mgl
dose
adjust
renal
impair
ceftriaxon
g
iv
im
q
h
cefotaxim
g
iv
h
adequ
strain
mic
mgl
new
formul
amoxicillinclavulan
acid
h
avail
european
countri
abl
erad
amoxicillinresist
strain
mic
mgl
shown
two
recent
random
clinic
trial
rct
macrolid
earss
databas
invas
pneumonia
isol
suscept
result
erythromycin
countri
report
data
isol
report
nonsuscept
erythromycin
three
countri
report
erythromycin
nonsuscept
czech
republ
n
estonia
n
bulgaria
n
hand
five
countri
report
nonsuscept
proport
name
itali
n
turkey
n
franc
n
hungari
n
cypru
n
pronounc
increas
erythromycin
resist
report
turkey
ireland
signific
select
laboratori
proport
isol
nonsuscept
erythromycin
belgium
franc
uk
continu
decreas
also
germani
netherland
norway
report
signific
decreas
rate
respect
see
fig
anoth
survey
time
period
highest
proport
pneumococci
suscept
erythromycin
report
malta
tunisia
macrolid
resist
pneumonia
occur
two
main
mechan
targetsit
modif
efflux
drug
cell
common
form
targetsit
modif
specif
adenin
residu
rrna
dimethyl
rrna
methylas
predomin
methylas
respons
macrolid
resist
pneumonia
encod
erm
b
methyl
thought
lead
conform
chang
ribosom
result
decreas
bind
macrolid
lincosamid
streptogramin
antibacteri
socal
mlsb
phenotyp
pneumococci
harbour
erm
b
gene
exhibit
high
high
level
resist
macrolid
clarithromycin
azithromycin
mg
l
macrolid
efflux
mediat
product
mef
gene
usual
caus
mic
lower
erm
b
isol
mic
mgl
retain
suscept
clindamycin
socal
mphenotyp
much
rare
mutat
differ
posit
domain
v
ii
rrna
gene
encod
ribosom
protein
identifi
caus
macrolid
resist
although
surpris
highli
resist
strain
mic
mgml
may
lead
clinic
failur
relev
lowlevel
resist
mic
mgml
brought
question
earli
decad
match
casecontrol
studi
patient
bacteraem
pneumococc
infect
show
breakthrough
bacteraemia
erythromycinresist
isol
occur
patient
take
macrolid
compar
none
match
patient
bacteraemia
erythromycinsuscept
isol
result
establish
macrolid
resist
among
pneumococci
includ
low
level
erythromycinresist
isol
phenotyp
caus
failur
outpati
pneumonia
therapi
recent
populationbas
casecontrol
studi
toronto
confirm
result
macrolid
resist
contribut
increas
risk
macrolid
failur
irrespect
underli
resist
mechan
degre
elev
erythromycin
mic
therefor
would
wise
avoid
empir
macrolid
therapi
patient
risk
infect
macrolideresist
pathogen
either
result
patientspecif
characterist
overal
rate
resist
commun
clinic
paramet
associ
macrolid
resist
among
pneumococci
includ
macrolid
exposur
within
previou
month
recent
use
penicillin
trimethroprimsulphamethoxazol
extrem
age
hiv
infect
exposur
sibl
colon
resist
isol
issu
whether
outcom
bacteraem
pneumococc
pneumonia
improv
use
combin
antibiot
therapi
vs
monotherapi
still
resolv
mechan
potenti
benefit
combin
macrolid
blactam
uncertain
may
multifactori
provid
cover
atyp
pathogen
unrecogn
polymicrobi
infect
andor
addit
cover
drugresist
infect
synergi
two
class
agent
immunomodulatori
properti
macrolid
macrolid
submic
class
antibiot
subvert
product
pneumolysin
even
presenc
irrespect
mechan
macrolid
resist
pneumonia
fluoroquinolon
resist
quinolon
occur
stepwis
fashion
mutat
observ
first
clinic
microbiolog
infect
volum
supplement
novemb
either
parc
gyra
lead
decreas
fluoroquinolon
suscept
strain
usual
becom
fulli
resist
addit
mutat
target
gene
either
gyra
parc
mutat
pare
gyrb
efflux
pump
less
import
mechan
resist
emerg
resist
cours
antimicrobi
therapi
like
develop
strain
alreadi
carri
one
quinolon
resist
determin
region
qrdr
requir
one
addit
mutat
one
target
gene
becom
resist
concept
mutant
prevent
concentr
reflect
concentr
prevent
growth
firststep
mutant
base
potenti
restrict
select
resist
mutant
fluoroquinolon
equal
classifi
accordingli
abil
prevent
select
mutant
descend
order
moxifloxacin
trovafloxacin
gatifloxacin
grepafloxacin
levofloxacin
fluoroquinolon
resist
among
pneumonia
remain
rare
europ
use
older
agent
incorrect
dose
main
driver
resist
alexand
project
report
fluoroquinolon
resist
among
pneumococci
northern
southern
europ
http
wwwalexandernetworkcom
protekt
studi
identifi
quinoloneresist
isol
northern
europ
pneumonia
southern
europ
resist
levofloxacin
http
wwwprotektorg
howev
preval
firststep
mutant
larg
unknown
recent
survey
suggest
preval
resist
levofloxacin
fluoroquinolon
moxifloxacin
gatifloxacin
southern
europ
specif
itali
spain
appear
around
tetracyclin
agent
mani
countri
world
chloramphenicol
cotrimoxazol
tetracyclin
reach
level
preval
resist
longer
good
option
empir
therapi
rti
pneumococc
aetiolog
thu
resist
trimethoprimsulphamethoxazol
report
approxim
isol
tetracyclin
resist
pneumococi
remain
rel
high
european
countri
howev
recent
comprehens
surveil
data
tetracyclin
resist
avail
earli
decad
among
invas
isol
report
resist
tetracyclin
among
noninvas
isol
preval
tetracyclin
resist
high
southern
europ
european
countri
recent
studi
shown
low
resist
rate
tetracyclin
resist
thu
uk
ireland
invas
isol
resist
among
respiratori
isol
resist
haemophilu
influenza
betalactam
blactamas
product
primari
mechan
resist
among
h
influenza
wellknown
predictor
treatment
failur
communityacquir
respiratori
tract
infect
overcom
use
blactamasest
cephalosporin
blactam
plu
blactamaseinhibitor
combin
addit
h
influenza
isol
carri
amino
acid
substitut
ftsi
gene
encod
pbp
phenotyp
recogn
blactamas
neg
ampicillin
resist
blnar
lead
loss
suscept
aminopenicillin
cephalosporin
europ
resist
rate
haemophilu
influenza
blactam
spite
larg
interregion
differ
seem
declin
due
decreas
number
blproduc
strain
recent
surveil
studi
antibiot
resist
h
influenza
mean
preval
blactam
produc
rang
although
rare
blactamaseneg
ampicillinresist
blnar
blactamaseposit
amoxicillinclavulanateresist
blpacr
h
influenza
concern
exist
macrolid
azithromycin
activ
agent
h
influenza
mic
fourto
eightfold
lower
erythromycin
azithromycin
mic
mgl
hand
exist
efflux
pump
lead
loss
suscept
macrolid
h
influenza
strain
appear
vast
major
h
influenza
strain
macrolid
efflux
mechan
hyperresist
azithromycin
mic
mgl
due
one
sever
ribosom
mutat
occasion
hypersuscept
strain
azithromycin
mic
mgl
found
without
underli
mechan
resist
appear
truli
macrolidesuscept
variant
h
influenza
preval
resist
base
use
pharmacokineticpharmacodynam
breakpoint
larg
discrep
observ
term
suscept
use
clsi
breakpoint
instanc
rate
suscept
clarithromycin
shift
use
pkpd
breakpoint
fluoroquinolon
agent
fluoroquinolon
resist
remain
rare
h
influenza
preval
tetracyclin
resist
recent
data
avail
survey
uk
ireland
show
signific
though
slow
downward
trend
p
tetracyclin
nonsuscept
reduc
dip
low
greec
resist
tetracyclin
increas
resist
oral
administ
agent
trimethoprimsulphamethoxazol
tmpsmx
chloramphenicol
well
known
overal
frequenc
resist
tmpsmx
remain
around
recent
survey
us
moraxella
catarrhali
suscept
catarrhali
chang
littl
sinc
interest
note
despit
almost
univers
blactamas
preval
resist
antibacteri
agent
develop
catarrhali
clinician
assum
isol
catarrhali
resist
amoxicillin
ampicillin
piperacillin
penicillin
two
type
blactamas
found
phenotyp
ident
type
enzym
readili
inactiv
blactamas
inhibitor
isol
still
suscept
amoxicillin
combin
clavulan
acid
enzymest
blactam
macrolid
tetracyclin
still
activ
catarrhali
rate
tmpsmx
resist
high
occasion
report
mycoplasma
pneumonia
pneumonia
inhibit
tetracyclin
macrolid
ketolid
fluoroquinolon
littl
variat
mic
among
clinic
isol
agent
activ
bacteri
ribosom
streptogramin
chloramphenicol
aminoglycosid
may
also
show
vitro
inhibitori
activ
pneumonia
normal
use
therapeut
purpos
organ
clindamycin
activ
vitro
vivo
activ
never
demonstr
due
lack
cell
wall
mycoplasma
resist
blactam
glycopeptid
sulphonamid
trimethoprim
polymixin
nalidix
acid
rifampin
also
inact
tetracyclin
fluoroquinolon
approv
use
children
macrolid
gener
consid
treatment
choic
pneumonia
infect
adult
children
sinc
emerg
macrolid
resist
report
mainli
asia
japan
sever
recent
studi
report
macrolideresist
pneumonia
isol
spread
sinc
preval
increas
accord
studi
mutat
domain
v
rrna
frequent
substitut
associ
macrolid
resist
clinic
isol
data
regard
current
resist
pattern
pneumonia
european
adult
adolesc
patient
cap
limit
macrolid
resist
rate
germani
recent
report
franc
among
pneumoniaeposit
specimen
collect
macrolideresist
pneumonia
isol
detect
contrast
among
sampl
collect
five
yield
resist
genotyp
suggest
recent
increas
macrolideresist
pneumonia
isol
franc
emerg
data
suggest
epidemiolog
monitor
macrolid
resist
speci
becom
necessari
europ
staphylococcu
aureu
european
set
aureu
remain
unusu
primari
caus
cap
although
import
caus
pneumonia
death
follow
influenza
role
camrsa
even
poorli
defin
although
emerg
europ
infect
due
camrsa
symptom
onset
within
h
admiss
hospit
patient
signific
previou
healthcar
contact
cap
due
camrsa
classic
present
young
previous
healthi
individu
rapidli
progress
sever
respiratori
diseas
aggress
natur
camrsa
due
toxin
product
caus
massiv
destruct
previous
normal
lung
camrsa
usual
resist
blactam
suscept
antibiot
class
differ
laboratori
find
may
indic
patient
camrsa
isol
oppos
hamrsa
isol
howev
time
camrsa
like
acquir
resist
gene
make
difficult
differenti
hamrsa
routin
antimicrobi
suscept
test
aureu
uncommon
caus
cap
need
cover
routin
empir
cap
treatment
howev
sever
associ
aureu
pneumonia
reinforc
import
perform
routin
blood
respiratori
cultur
pneumonia
patient
clindamycin
linezolid
markedli
suppress
format
pvl
ahaemolysin
toxic
shock
syndrom
toxin
suppress
translat
transcript
nafcillin
hand
stimul
toxin
product
wherea
toxin
level
use
vancomycin
compar
control
sampl
expos
antibiot
suppress
toxin
product
may
correl
improv
outcom
vancomycin
alon
may
optim
treatment
pneumonia
caus
toxinproduc
camrsa
although
establish
combin
bactericid
agent
toxinsuppress
agent
clindamycin
linezolid
associ
improv
outcom
gener
feel
vancomycin
use
singl
agent
treatment
camrsa
cap
sever
infect
limit
trial
data
support
use
one
regimen
anoth
recommend
larg
base
expert
advic
adjunct
therapi
intraven
immunoglobulin
success
case
report
real
contribut
unknown
new
inform
avail
clinic
relev
antimicrobi
resist
set
pattern
antimicrobi
resist
vari
european
countri
chang
preval
antibiot
resist
among
main
respiratori
pathogen
europ
report
continu
surveil
antimicrobi
resist
common
pathogen
essenti
pneumococci
erythromycin
mic
mgl
predict
clinic
failur
preval
resist
mani
countri
compromis
efficaci
macrolid
treatment
pneumococc
infect
preval
resist
dictat
need
reassess
current
recommend
treatment
cap
role
camrsa
cap
poorli
defin
although
emerg
europ
camrsa
usual
resist
blactam
suscept
antibiot
class
antibiot
treatment
camrsa
pneumonia
known
suppress
toxin
product
may
correl
improv
outcom
vancomycin
alon
may
optim
treatment
pneumonia
thu
combin
bactericid
agent
toxinsuppress
agent
clindamycin
linezolid
suggest
optim
choic
vivo
select
resist
mean
proper
use
antimicrobi
essenti
new
inform
need
high
levofloxacin
dose
mg
od
treatment
pseudomona
klebsiella
two
new
studi
alter
current
guidelin
recommend
lower
respiratori
tract
infect
broad
descript
group
diseas
entiti
encompass
acut
bronchiti
pneumonia
exacerb
chronic
lung
diseas
primari
care
difficult
differenti
differ
diseas
without
extens
addit
diagnost
test
patient
present
cough
dyspnoea
tachypnoea
fever
pain
chest
wheez
auscultatori
abnorm
huge
overlap
present
differ
lower
respiratori
diseas
mention
neither
feasibl
costeffici
full
diagnost
workup
patient
therefor
empir
pragmat
approach
warrant
statement
recommend
base
primari
care
studi
expert
opinion
consensu
among
member
work
group
aspir
pneumonia
consid
recommend
aspir
pneumonia
consid
patient
difficulti
swallow
show
sign
acut
lrti
patient
chest
xray
perform
new
inform
recommend
chang
left
ventricular
failur
consid
recommend
left
ventricular
failur
consid
patient
either
orthopnoea
displac
apex
beat
andor
histori
myocardi
infarct
hypertens
atrial
fibril
low
serum
level
atrial
natriuret
peptid
brain
natriucet
peptid
pgml
ntermin
probnp
pgmg
make
presenc
left
ventricular
failur
unlik
new
inform
recommend
chang
number
new
studi
diagnosi
cardiac
failur
primari
care
found
none
involv
patient
cough
presenc
hypertens
atrial
fibril
associ
cardiac
failur
level
bnp
ntprobnp
found
diagnost
valu
detect
cardiac
failur
evid
assess
diagnost
accuraci
cardiac
peptid
detect
left
ventricular
dysfunct
lvd
patient
refer
primari
care
suspect
hf
institut
medic
therapi
fuat
et
al
test
compar
diagnost
accuraci
util
btype
natriuret
peptid
bnp
ntermin
btype
natriuret
peptid
nt
probnp
diagnos
heart
failur
due
left
ventricular
systol
dysfunct
patient
suspect
heart
failur
refer
gp
onestop
diagnost
clinic
pulmonari
embol
consid
recommend
pulmonari
embol
consid
patient
one
follow
characterist
histori
dvt
pulmonari
embol
immobil
past
week
malign
diseas
new
inform
recommend
chang
chronic
airway
diseas
consid
recommend
patient
persist
cough
least
two
follow
wheez
either
sign
symptom
previou
consult
wheez
cough
dyspnoea
prolong
expir
smoke
histori
symptom
allergi
lungfunct
test
consid
assess
presenc
chronic
airway
diseas
elderli
patient
smoke
present
cough
copd
consid
one
relev
studi
indic
smoke
age
year
combin
cough
clearli
relat
presenc
copd
one
literatur
review
recent
publish
gave
critic
report
six
studi
detect
copd
follow
sign
symptom
mention
least
three
time
studi
dyspnoea
wheez
complaint
previou
consult
wheez
cough
selfreport
copd
age
smoke
wheez
sign
prolong
expirium
forc
expir
time
review
conclud
variat
weak
studi
design
warrant
studi
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
object
design
evid
van
schayck
et
al
investig
effect
case
find
patient
risk
develop
chronic
obstruct
pulmonari
diseas
broekhuizen
et
al
review
literatur
detect
copd
patient
cough
primari
care
differenti
pneumonia
respiratori
tract
infect
recommend
patient
suspect
pneumonia
one
follow
sign
symptom
present
new
focal
chest
sign
dyspnoea
tachypnoea
puls
rate
fever
day
patient
suspect
pneumonia
test
serumlevel
creactiv
protein
crp
done
crp
level
mgl
present
symptom
h
make
presenc
pneumonia
highli
unlik
level
mgl
make
pneumonia
like
case
persist
doubt
crp
test
chest
xray
consid
confirm
reject
diagno
two
new
studi
diagnost
valu
sign
symptom
crp
show
combin
sign
symptom
crp
diagnost
valu
detect
mainli
rule
pneumonia
two
new
studi
isol
diagnost
valu
crp
confirm
diagnost
valu
crp
hand
two
review
valu
crp
field
conclud
crp
clear
diagnost
valu
primari
care
review
van
der
meer
et
al
howev
found
excel
posit
neg
predict
valu
roc
curv
area
curv
falk
et
al
conclud
review
isol
use
crp
use
primari
care
state
nevertheless
discuss
physician
doubt
presenc
pneumonia
crp
could
help
rule
diseas
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
evalu
diagnost
accuraci
creactiv
protein
detect
radiolog
prove
pneumonia
evalu
well
discrimin
bacteri
viral
infect
lower
respiratori
tract
graffelman
et
al
assess
diagnost
valu
sign
symptom
crp
detect
pneumonia
holm
et
al
evalu
diagnost
valu
crp
procalcitonin
detect
pneumonia
falk
fahey
one
new
updat
cochran
review
cough
medic
conclud
clear
benefit
intervent
studi
review
report
benefici
effect
expector
antitus
agent
studi
small
suffer
methodolog
flaw
cochran
review
use
bronchodil
acut
cough
show
benefici
effect
one
new
rct
effect
inhal
fluticason
patient
acut
cough
show
small
effect
symptom
sever
second
week
diseas
clinic
relev
small
effect
howev
doubt
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
refer
object
design
evid
smith
et
al
assess
effect
oral
overthecount
cough
prepar
acut
cough
smucni
et
al
determin
whether
improv
symptom
acut
bronchiti
patient
underli
pulmonari
diseas
ponsioen
et
al
investig
shortterm
effect
inhal
steroid
fluticason
propion
fp
cough
antibiot
treatment
consid
patient
lrti
recommend
antibiot
treatment
prescrib
patient
suspect
definit
pneumonia
see
differenti
pneumonia
respiratori
tract
infect
antibiot
treatment
consid
patient
lrti
seriou
comorbid
one
new
updat
cochran
review
effect
antibiot
acut
bronchiti
includ
one
larg
new
trial
effect
antimicrobi
therapi
new
conclus
overal
effect
averag
adult
patient
acut
bronchiti
recommend
subgroup
base
consensu
evid
estim
effect
three
prescrib
strategi
inform
leaflet
acut
lower
respiratori
tract
infect
rct
smith
assess
effect
antibiot
treatment
patient
clinic
diagnosi
acut
bronchiti
indic
antibiot
treatment
acut
exacerb
chronic
obstruct
lung
diseas
copd
recommend
antibiot
given
exacerb
copd
patient
three
follow
symptom
increas
dyspnoea
sputum
volum
sputum
purul
addit
antibiot
consid
exacerb
patient
sever
copd
new
inform
recommend
chang
new
cochran
review
conclud
antibiot
treatment
benefici
effect
moder
sever
ill
patient
increas
cough
purul
sputum
howev
author
state
conclus
somewhat
weaken
consider
differ
methodolog
set
studi
three
studi
outpati
indic
potenti
benefici
effect
patient
three
anthonisen
criteria
evid
antibiot
use
patient
lrti
recommend
amoxicillin
tetracyclin
use
antibiot
first
choic
base
least
chanc
harm
wide
experi
clinic
practic
case
hypersensit
tetracyclin
macrolid
azithromycin
clarithromycin
erythromycin
roxithromycin
good
altern
countri
low
pneumococc
macrolid
resist
nationalloc
resist
rate
consid
choos
particular
antibiot
clinic
relev
bacteri
resist
rate
firstchoic
agent
treatment
levofloxacin
moxifloxacin
may
consid
clear
prefer
avail
antibiot
given
base
shortterm
benefit
frequenc
sideeffect
clinic
trial
assess
effect
antibiot
primari
care
vari
consider
qualiti
method
regard
report
sideeffect
advers
event
subject
equal
realli
possibl
compar
tendenc
evok
bacteri
resist
rare
import
sideeffect
avail
antibiot
agent
activ
respiratori
pathogen
caus
bacteri
resist
follow
recommend
newer
broadspectrum
antibiot
reserv
secondchoic
escap
medic
tradit
wellknown
agent
use
two
new
review
support
recommend
evid
recent
public
shown
curbscor
modif
particularli
score
compar
pneumonia
sever
index
index
term
predict
death
pneumonia
outpati
inpati
moreov
shown
outperform
gener
sepsi
earli
warn
score
view
simplic
absenc
laboratori
radiograph
criterion
may
easili
avail
gener
practic
score
recommend
tool
choic
assess
pneumonia
sever
systol
blood
pressur
best
haemodynam
predictor
diastol
pressur
may
neglect
prioriti
clinic
judgement
need
consid
nonclin
factor
decis
make
treatment
set
reinforc
patient
resid
nurs
home
predefin
clinic
pathway
help
reduc
hospit
compar
clinic
outcom
biomark
creactiv
protein
crp
procalcitonin
pct
ddimer
carboxytermin
provasopressin
ctproavo
copeptin
midregion
proatrial
natriuret
peptid
mrproanp
midregion
proadrenomedullin
mradm
trigger
receptor
express
myeloid
cell
well
adren
respons
altern
addit
tool
assess
pneumonia
sever
recent
gain
much
attent
appear
seem
signific
potenti
predict
mortal
data
suggest
predict
tool
biomark
reflect
ident
process
biomark
may
improv
predict
base
clinic
paramet
howev
optim
use
clinic
assess
includ
sever
score
biomark
remain
establish
current
crp
pct
best
avail
may
implement
addit
sever
tool
howev
evid
still
limit
among
biomark
investig
proadm
seem
promis
evid
admiss
ddimer
identifi
lowrisk
patient
communityacquir
pneumonia
pc
christcrain
et
al
proadrenomedullin
predict
sever
outcom
communityacquir
pneumonia
pc
christcrain
et
al
free
total
cortisol
level
predictor
sever
outcom
communityacquir
pneumonia
pc
christcrain
et
al
use
btype
natriuret
peptid
risk
stratif
communityacquir
pneumonia
pc
hirakata
et
al
comparison
use
plasma
procalcitonin
creactiv
protein
measur
estim
sever
adult
communityacquir
pneumonia
rc
hohenth
et
al
util
creactiv
protein
assess
diseas
sever
complic
communityacquir
pneumonia
holm
et
al
procalcitonin
vs
creactiv
protein
predict
pneumonia
adult
lower
respiratori
tract
infect
primari
care
huang
et
al
midregion
proadrenomedullin
prognost
tool
communityacquir
pneumonia
pc
menendez
et
al
biomark
improv
mortal
predict
prognost
scale
communityacquir
pneumonia
okimoto
et
al
procalcitonin
sever
communityacquir
pneumonia
kruger
et
al
proatrial
natriuret
peptid
provasopressin
predict
sever
prognosi
communityacquir
pneumonia
result
german
compet
network
capnetz
kruger
et
al
procalcitonin
predict
potenti
rule
predict
icu
admiss
depend
local
facil
therefor
appear
sever
criteria
use
indic
need
intens
care
treatment
rather
care
special
unit
presenc
least
two
systol
blood
pressur
mmhg
sever
respiratori
failur
pao
f
involv
two
lobe
chest
radiograph
multilobar
involv
one
requir
mechan
ventil
requir
vasopressor
h
septic
shock
indic
sever
cap
altern
presenc
sever
minor
criteria
provid
last
idsaat
updat
may
indic
sever
cap
rule
increas
attent
given
recognit
patient
unstabl
cours
pneumonia
order
avoid
delay
transfer
icu
extern
valid
modifi
at
rule
well
rule
eg
idsaat
rule
smartcop
rule
result
two
import
insight
first
rule
abl
account
import
sever
criteria
could
justifi
icu
admiss
without
substanti
loss
specif
second
decis
admit
icu
usual
exclus
base
clinic
criteria
also
depend
local
set
facil
therefor
appear
criteria
icu
admiss
use
indic
need
intensifi
treatment
ie
monitor
treatment
acut
respiratori
failur
andor
sever
sepsi
rather
advic
icu
admiss
wherea
score
shown
consist
superior
other
score
reli
socal
minor
criteria
prefer
least
clinic
use
avoid
reli
tautolog
major
criteria
pneumonia
sever
rule
psi
use
identifi
patient
sever
pneumonia
view
wors
prognosi
patient
delay
transfer
icu
compar
direct
transfer
patient
close
monitor
within
intensifi
treatment
offer
patient
risk
progress
diseas
howev
still
major
need
predictor
patient
deterior
recent
develop
reaicu
index
still
await
valid
independ
cohort
differ
set
current
close
monitor
patient
risk
within
intensifi
treatment
best
measur
identifi
patient
consecut
measur
crp
assess
oxygen
may
use
followup
assess
treatment
respons
haemophilu
influenza
variou
percentag
organ
recov
diminish
order
frequenc
gramneg
aerob
streptococci
pyogen
staphylococcu
aureu
mixtur
organ
latter
difficult
decid
whether
present
bloodstream
skin
contamin
retrospect
observ
cohort
studi
hospit
patient
admit
via
emerg
depart
treatment
pneumonia
true
posit
blood
cultur
combin
result
studi
six
studi
patient
antibiot
chang
base
posit
blood
cultur
studi
demonstr
limit
util
blood
cultur
cap
patient
howev
includ
mani
patient
risk
multidrugresist
pathogen
systemat
review
studi
total
adult
patient
admit
cap
conclud
blood
cultur
rare
alter
empir
antibiot
therapi
even
chang
mostli
like
impact
patient
outcom
find
systemat
review
support
obtain
blood
cultur
adult
hospit
cap
howev
also
systemat
review
investig
exclud
immunocomprom
highrisk
group
could
bias
result
blood
cultur
util
would
prudent
therefor
gener
find
addit
studi
includ
review
observ
prospect
requir
blood
cultur
patient
admit
cap
sever
studi
explicitli
requir
two
set
blood
cultur
blood
cultur
done
prior
antibiot
may
reveal
maximum
util
blood
cultur
methicilinresist
staphylococcu
aureu
mrsa
previous
confin
nosocomi
infect
becom
preval
commun
caus
communityassoci
mrsa
infect
includ
cap
recent
year
healthi
young
peopl
without
tradit
risk
factor
aureu
diseas
present
increasingli
sever
mrsa
cap
associ
high
mortal
mani
strain
contain
toxin
pantonvalentin
leucocidin
gene
specimen
includ
blood
cultur
obtain
diagnost
antimicrobi
drug
suscept
test
order
target
therapi
new
inform
recommend
chang
el
sohl
studi
nurs
home
patient
requir
mechan
ventil
suspect
pneumonia
evalu
quantit
endotrach
aspir
comparison
psb
bal
specimen
studi
show
qea
correl
well
quantit
bronchoscop
psb
bal
diagnost
accuraci
favour
cfuml
may
reliabl
altern
psb
bal
patient
admit
nurs
home
requir
ventil
bronchoscop
procedur
feasibl
avail
accept
sputum
specimen
obtain
effort
approxim
patient
inhal
hyperton
salin
induc
secret
cough
valu
gram
stain
accept
sputum
specimen
depend
presenc
predomin
bacteri
morphotyp
retrospect
cohort
studi
sputum
examin
use
diagnost
tool
minor
patient
without
notic
benefit
clinic
manag
cap
inpati
studi
anevlavi
first
report
studi
amount
inform
concern
oper
characterist
diagnost
valu
sputum
gram
stain
patient
bacteraem
cap
sensit
sputum
gram
stain
pneumococc
pneumonia
staphylococc
pneumonia
haemophilu
influenza
pneumonia
specif
rang
data
studi
suggest
properli
collect
read
gram
stain
provid
simpl
readili
avail
rapid
inexpens
test
result
depend
test
earli
aetiolog
diagnosi
bacteri
pneumonia
bacteraem
patient
infect
aspergillu
spp
distinguish
colon
presenc
hypha
respiratori
specimen
diagnosi
aspergillosi
still
base
detect
circul
antigen
serum
evid
recommend
cultur
cultur
purul
sputum
specimen
bacteri
speci
compat
morphotyp
observ
gram
stain
process
correctli
consid
confirm
speci
identif
antibiot
suscept
test
new
inform
recommend
chang
sensit
specif
sputum
cultur
reduc
contamin
flora
colon
upper
respiratori
tract
valu
sputum
cultur
establish
bacteri
caus
lrti
depend
specimen
collect
process
whether
predomin
bacteri
morphotyp
observ
gram
stain
antigen
test
offer
diagnosi
communityacquir
pneumonia
recommend
immunochromatograph
urinari
antigen
test
pneumonia
perform
patient
admit
hospit
reason
ill
sever
test
also
consid
whenev
pleural
fluid
sampl
obtain
set
parapneumon
effus
urin
l
pneumophila
serogroup
antigen
detect
perform
patient
admit
hospit
reason
sever
patient
infect
clinic
epidemiolog
suspect
l
pneumophila
serogroup
antigen
detect
urin
rapid
method
diagnos
exclud
infect
neg
test
make
legionella
unlik
exclud
legionella
infect
valu
pneumonia
urinari
antigen
test
adult
sensit
specif
howev
weak
posit
result
interpret
caution
relationship
degre
pneumonia
urinari
antigen
test
posit
pneumon
sever
index
therefor
cost
save
test
could
appli
sequenti
manner
reserv
test
highrisk
patient
demonstr
result
sputum
gram
stain
unavail
pneumonia
type
specif
urinari
antigen
identifi
serotyp
involv
also
prospect
cohort
studi
report
kobashi
pneumococc
urinari
immunochromatograph
test
ict
increas
diagnost
yield
pneumococc
pneumonia
patient
cap
particularli
use
diagnos
patient
poor
qualiti
sputum
antibiot
treatment
nevertheless
select
studi
author
abl
establish
clinic
impact
rapid
simplic
ict
test
pneumococc
pneumonia
pneumonia
caus
pneumonia
also
appear
treat
safe
effect
highdos
penicillin
base
posit
result
urinari
antigen
test
retrospect
studi
report
oka
even
compar
pcr
blood
sampl
binax
pneumonia
urinari
antigen
test
sensit
rapid
test
earli
diagnosi
bacteraem
pneumococc
pneumonia
persist
pneumonia
antigenuria
follow
diagnosi
pneumococc
pneumonia
normal
prolong
especi
concentr
urin
use
effect
pretreat
antibiot
result
contradictori
report
lower
detect
rate
one
studi
increas
detect
rate
test
perform
h
initi
antibiot
treatment
urinari
antigen
test
may
also
carri
pleural
fluid
sensit
specif
respect
serum
sampl
sensit
bacteraem
patient
nonbacteraem
patient
ict
test
perform
pleural
fluid
sampl
augment
standard
diagnost
method
blood
pleural
fluid
cultur
even
case
prior
antibiot
therapi
enhanc
ict
urinari
antigen
test
may
provid
addit
inform
beyond
obtain
measur
urin
sampl
alon
vice
versa
therefor
test
consid
whenev
pleural
fluid
sampl
obtain
set
parapneumon
effus
particularli
urinari
antigen
test
contributori
vaccin
result
posit
urinari
antigen
test
urinari
antigen
detect
current
help
rapid
test
diagnosi
legionella
infect
immunochromatograph
format
better
suit
singl
specimen
produc
result
within
minut
one
report
differ
urinari
antigen
test
ident
sensit
second
report
result
test
differ
perform
unconcentr
urin
sampl
ident
perform
concentr
urin
specimen
studi
olsen
binax
test
significantli
higher
sensit
biotest
kit
l
pneumophila
serogroup
one
speci
nonl
pneumophila
speci
nonserogroup
l
pneumophila
new
legionella
antigen
test
develop
becom
avail
show
perform
compar
binax
test
could
altern
detect
l
pneumophila
antigen
urin
patient
suspect
legionella
pneumonia
sinc
urinari
antigen
test
introduc
earli
diagnosi
treatment
help
improv
outcom
case
fatal
rate
case
involv
outbreak
legionellosi
legionella
infect
also
exist
relationship
degre
posit
urinari
antigen
test
sever
diseas
posit
result
urinari
antigen
test
demonstr
capnetz
studi
associ
sever
clinic
cours
lead
potenti
relev
underrecognit
speci
l
pneumophila
rapid
antigen
test
respiratori
specimen
diagnosi
influenza
viru
infect
adult
patient
insensit
consequ
limit
valu
confirm
clinic
microbiolog
infect
volum
supplement
novemb
diagnosi
influenza
clinic
suspect
adult
accord
one
studi
howev
studi
falsey
clearli
show
rapid
influenza
test
lead
reduct
antibiot
use
hospit
adult
evid
one
studi
pcrdocument
pneumonia
infect
diagnos
acut
convalesc
phase
sera
respect
anoth
studi
antim
pneumonia
igm
antibodi
detect
depend
test
appli
acut
sera
igg
antibodi
convalesc
sera
although
igm
detect
acut
phase
show
moder
sensit
provid
specif
test
use
combin
igm
antibodi
detect
pcr
may
sensit
approach
diagnos
mycoplasma
pneumonia
infect
demonstr
studi
martinez
capnetz
studi
also
acut
lrti
due
c
pneumonia
combin
pcr
detect
specif
singl
serum
igm
measur
seem
recommend
also
recent
studi
legionella
antibodi
detect
confirm
diagnosi
base
one
serum
sampl
patient
serolog
base
pair
sera
case
confirm
rather
late
cours
diseas
advis
use
diagnost
test
combin
serolog
comparison
evalu
four
commerci
kit
rel
inhous
immunofluoresc
test
detect
antibodi
legionella
pneumophila
amplif
test
use
diagnosi
lrti
recommend
avail
applic
quantit
molecular
test
detect
streptococcu
pneumonia
sputum
blood
may
valuabl
cap
patient
antibiot
therapi
initi
may
use
tool
sever
assess
applic
molecular
test
detect
influenza
rsv
consid
winter
season
detect
atyp
pathogen
provid
test
valid
result
obtain
suffici
rapidli
therapeut
relev
qualit
nucleic
acid
amplif
test
naat
pneumonia
pleural
fluid
peripher
blood
sputum
add
littl
exist
diagnost
test
sputum
unabl
distinguish
colon
infect
recent
prospect
studi
realtim
quantit
pcr
rqpcr
evalu
sputum
sampl
patient
cap
admit
hospit
yield
rqpcr
almost
twice
high
sputum
cultur
patient
proven
pneumococc
aetiolog
figur
suggest
hospitaltr
cap
patient
sputum
pcr
sensit
method
detect
pneumonia
sputum
cultur
previous
chosen
cutoff
level
correspond
cfuml
confirm
especi
antibiot
treatment
initi
rqpcr
togeth
urin
antigen
detect
best
method
identifi
pneumonia
detect
pneumonia
specif
target
realtim
pcr
assay
lyta
plasma
also
use
rapid
detect
bacteraem
pneumococc
pneumonia
detect
bacteri
dna
load
whole
blood
support
diagnosi
pneumonia
infect
patient
cap
bacteri
load
associ
likelihood
death
risk
septic
shock
need
mechan
ventil
high
genom
bacteri
load
pneumonia
may
use
tool
sever
assess
realtim
pcr
detect
haemophilu
influenza
sensit
specif
detect
haemophilu
influenza
respiratori
secret
quantif
facilit
discrimin
diseasecaus
h
influenza
strain
commens
colon
quantit
pcr
assay
also
shown
use
diagnosi
cap
case
caus
l
pneumophila
although
lower
sensit
urinari
antigen
test
rqpcr
antigen
test
consid
complementari
diagnost
armamentarium
legionellosi
high
bacteri
load
determin
rqpcr
lrt
sampl
use
predict
diseas
sever
may
advantag
techniqu
therefor
warrant
investig
naat
pneumonia
c
pneumonia
l
pneumophila
b
pertussi
prefer
sputum
valid
addit
l
pneumophilaspecif
pcr
urinari
antigen
test
use
patient
suspect
legionnair
diseas
produc
sputum
might
allow
earli
detect
signific
number
addit
patient
detect
pneumonia
cap
lrti
case
pcr
less
sensit
serolog
one
studi
superior
serolog
especi
earli
phase
infect
anoth
studi
data
analysi
differ
studi
indic
singl
avail
test
reliabl
identif
pneumonia
cap
combin
serolog
pcr
prove
reliabl
approach
identif
pneumonia
also
acut
lrti
caus
c
pneumonia
combin
pcr
detect
specif
singl
serum
igm
measur
seem
recommend
use
bordetella
pertussi
specif
pcr
combin
singleserum
serolog
combin
cultur
pcr
increas
sensit
pertussi
diagnosi
clinic
microbiolog
infect
volum
supplement
novemb
result
recent
studi
confirm
previou
find
addit
pcrbase
method
convent
microbi
techniqu
improv
yield
aetiolog
agent
significantli
indic
pcr
rapid
convent
method
also
sensit
aetiolog
diagnosi
cap
detect
respiratori
virus
lrti
allow
clinician
initi
optim
symptomat
treatment
ration
use
antibiot
adequ
antivir
therapi
indic
optim
infect
control
previous
unknown
virus
discov
sever
coronavirus
human
metapneumoviru
bocaviru
detect
cap
naat
report
infect
mixtur
sever
virus
infect
mixtur
virus
bacteria
exist
systemat
comprehens
studi
await
defin
clinic
import
viral
mix
infect
respiratori
syncyti
viru
outbreak
longterm
care
facil
detect
use
revers
transcriptas
polymeras
chain
reaction
argument
realtim
detect
method
classif
use
treatment
recommend
antimicrobi
treatment
empir
follow
approach
accord
individu
risk
mortal
assess
sever
accord
mild
moder
sever
pneumonia
impli
decis
appropri
treatment
set
ambulatori
hospit
ward
icu
antimicrobi
treatment
initi
soon
possibl
guidanc
empir
initi
antimicrobi
treatment
follow
three
basic
consider
overal
ten
criteria
prognost
assess
assess
age
patient
age
year
subdivid
moderategood
abil
sever
disabl
ideal
assess
follow
establish
score
eg
adl
score
roughli
sever
disabl
patient
may
defin
bedridden
assess
gener
prognosi
patient
pneumonia
expect
termin
event
sever
comorbid
manag
along
principl
palli
medicin
b
assess
correct
group
previou
hospit
antimicrobi
treatment
patient
hospit
month
ago
repeat
recent
antimicrobi
treatment
classifi
nosocomi
pneumonia
treat
accordingli
risk
factor
sever
immunosuppress
ie
risk
opportunist
pathogen
patient
manag
follow
guidelin
immunocompromis
patient
c
assess
factor
determin
select
antimicrobi
treatment
sever
although
sever
minor
impact
microbi
pattern
broad
combin
treatment
mandatori
order
cover
potenti
pathogen
prevent
excess
mortal
due
treatment
failur
comorbid
comorbid
may
independ
bear
potenti
underli
pathogen
resid
nurs
home
resid
may
alter
microbi
pattern
risk
assess
individu
aspir
may
wit
suspect
may
correspond
gross
silent
aspir
region
local
pattern
microbi
preval
resist
consider
toler
toxic
antimicrobi
agent
individu
patient
antibiot
administ
diagnosi
pneumonia
recommend
antibiot
treatment
initi
immedi
diagnosi
cap
patient
cap
septic
shock
delay
must
h
diagnosi
consequ
studi
suggest
advers
prognost
effect
delay
antimicrobi
treatment
immedi
time
administr
antibiot
advoc
patient
cap
suggest
indic
qualiti
although
earli
antibiot
treatment
confirm
advantag
author
heavili
challeng
studi
fail
confirm
disadvantag
delay
antibiot
treatment
other
question
practic
view
question
feasibl
polici
high
rate
misdiagnosi
overtreat
american
academi
emerg
medicin
recommend
measur
time
first
antibiot
dose
cap
discontinu
author
confirm
misdiagnosi
overtreat
along
report
antibiot
time
distinct
diagnosi
pneumonia
seem
mandatori
initi
antibiot
treatment
appear
prognost
relev
antibiot
time
highest
patient
higher
risk
death
aminopenicillin
macrolid
b
aminopenicillinblactamas
inhibitor
macrolid
b
nonantipseudomon
cephalosporin
cefotaxim
ceftriaxon
macrolid
b
levofloxacin
moxifloxacin
c
penicillin
g
macrolid
appli
sequenti
treatment
use
drug
b
new
macrolid
prefer
erythromycin
c
within
fluoroquinolon
moxifloxacin
highest
antipneumococc
activ
patient
risk
gneb
particularli
strain
esbl
without
risk
exclus
p
aeruginosa
ertapenem
may
use
sever
public
demonstr
lowlevel
pneumococc
resist
penicillin
associ
advers
outcom
treatment
patient
communityacquir
pneumonia
resist
macrolid
may
relev
patient
moder
sever
pneumonia
therefor
choic
antimicrobi
agent
base
consider
allergi
intoler
previou
use
penicillin
macrolid
quinolon
cost
potenti
advers
effect
rather
pencillin
resist
clinic
microbiolog
infect
volum
supplement
novemb
sever
retrospect
studi
suggest
superior
blactammacrolid
combin
therapi
hospit
patient
particularli
sever
diseas
howev
definit
conclus
made
present
data
therefor
appear
combin
treatment
restrict
patient
higher
risk
class
rule
thumb
sever
patient
present
stronger
recommend
combin
treatment
new
formul
amoxicillinclavulan
acid
avail
instead
offer
advantag
higher
penicillin
dose
may
particularli
advantag
patient
pneumococc
pneumonia
resist
lowlevel
penicillin
respiratori
quinolon
establish
treatment
option
howev
potenti
small
superior
respiratori
quinolon
compar
penicillin
macrolid
must
balanc
concern
select
pressur
cost
note
absenc
pneumococc
coverag
ciprofloxacin
contraind
treatment
communityacquir
pneumonia
emea
limit
use
oral
moxifloxacin
although
state
benefit
continu
outweigh
risk
state
prescrib
antibiot
use
fail
recommend
made
mainli
view
increas
risk
advers
hepat
reaction
evid
literatur
moxifloxacin
consid
differ
levofloxacin
regard
moreov
evid
liver
toxic
higher
amoxicillinclavulan
acid
respiratori
quinolon
two
addit
agent
investig
patient
cap
tigecyclin
ertapenem
howev
concern
low
serum
level
tigecyclin
standard
dosag
might
hazard
bacteraem
pneumonia
ertapenem
seem
attract
choic
patient
risk
gramneg
enterobacteriacea
gneb
infect
particularli
esblproduc
strain
risk
pseudomona
aeruginosa
infect
regular
coverag
atyp
pathogen
may
necessari
nonsever
hospit
patient
treatment
option
patient
sever
communityacquir
pneumonia
icu
intermedi
care
risk
factor
p
aeruginosa
nonantipseudomon
cephalosporin
iii
macrolid
moxifloxacin
levofloxacin
nonantipseudomon
cephalosporin
iii
risk
factor
p
aeruginosa
antipseudomon
cephalosporin
b
acylureidopenicillinblactamas
inhibitor
carbapenem
meropenem
prefer
g
possibl
infus
plu
ciprofloxacin
c
plu
macrolid
aminoglycosid
gentamicin
tobramycin
amikacin
new
macrolid
prefer
erythromycin
b
ceftazidim
combin
penicillin
g
coverag
pneumonia
c
levofloxacin
h
mg
twice
daili
altern
also
cover
gramposit
bacteria
treatment
empir
control
trial
avail
patient
treat
icu
meet
predict
rule
sever
cap
combin
treatment
offer
advantag
monotherapi
expand
antimicrobi
coverag
probabl
immunomodul
macrolid
quinolon
therefor
treatment
choic
howev
respiratori
quinolon
may
use
monotherapi
sever
pneumonia
without
septic
shock
incid
cap
p
aeruginosa
seem
low
patient
risk
factor
p
aeruginosa
meropenem
offer
advantag
imipenem
option
increas
dose
significantli
g
patient
risk
cap
p
aeruginosa
alway
treat
two
antipseudomon
drug
order
reduc
chanc
inadequ
treatment
pathogen
isol
suscept
test
combin
treatment
may
deescal
monotherapi
addit
macrolid
betalactambas
empir
antibiot
regimen
associ
lower
inhospit
mortal
patient
bacteraem
pneumococc
pneumonia
romanelli
et
al
carbapenem
treatment
sever
communityacquir
pneumonia
hospit
elderli
patient
compar
studi
standard
therapi
rzeszutek
et
al
review
clinic
failur
associ
macrolideresist
streptococcu
pneumonia
shefet
et
al
empir
antibiot
coverag
atyp
pathogen
communityacquir
pneumonia
hospit
adult
wasserfallen
et
al
costeffect
fullcours
oral
levofloxacin
sever
communityacquir
pneumonia
weiss
tillotson
controversi
combin
vs
monotherapi
treatment
hospit
communityacquir
pneumonia
still
convinc
evid
discord
treatment
penicillinresist
pneumococci
neg
affect
clinic
outcom
thu
pencillin
may
still
use
target
treatment
pneumococci
resist
mic
mgl
recent
public
confirm
respiratori
quinolon
particularli
levofloxacin
offer
advantag
macrolid
treatment
legionella
infect
macrolid
use
azithromycin
prefer
drug
superior
levofloxacin
azithromycin
relev
patient
sever
legionellosi
evid
focu
recent
studi
deal
treatment
durat
assess
postdischarg
outcom
european
author
report
declin
durat
hospit
therefor
iv
treatment
comorbid
particularli
cardiopulmonari
neurolog
condit
associ
rehospit
treatment
failur
due
inadequ
short
iv
treatment
durat
hand
ongo
clinic
inflamm
despit
clinic
recoveri
describ
howev
improb
level
inflamm
influenc
prolong
treatment
durat
patient
hospit
nonsever
pneumonia
appropri
treat
day
antibiot
although
one
studi
address
treatment
durat
nosocomi
pneumonia
appear
reason
believ
treatment
durat
sever
pneumonia
differ
nosocomi
pneumonia
accord
studi
day
appear
compar
day
treatment
howev
presenc
p
aeruginosa
nonferment
clinician
must
awar
increas
risk
relaps
recent
biomark
describ
use
tool
safe
reduc
antibiot
treatment
durat
biomark
guid
treatment
durat
applic
predefin
stop
rule
antibiot
shown
rule
work
even
sever
case
includ
pneumonia
septic
shock
even
clinician
allow
overrul
predefin
stop
rule
procalcitonin
guidanc
antibiot
therapi
communityacquir
pneumonia
random
trial
el
moussaoui
et
al
comparison
day
day
intraven
amoxicillin
jasti
et
al
caus
risk
factor
rehospit
patient
hospit
communityacquir
pneumonia
kristoffersen
et
al
antibiot
treatment
interrupt
suspect
lower
respiratori
tract
infect
base
singl
procalcitonin
measur
hospit
admissiona
random
trial
nobr
et
al
use
procalcitonin
shorten
antibiot
treatment
durat
septic
patient
random
trial
schuetz
et
al
effect
procalcitoninbas
guidelin
vs
standard
guidelin
antibiot
use
lower
respiratori
tract
infect
prohosp
random
control
trial
yend
et
al
inflammatori
marker
hospit
discharg
predict
subsequ
mortal
pneumonia
sepsi
iv
treatment
use
switch
oral
occur
recommend
ambulatori
pneumonia
treatment
appli
oral
begin
care
select
hospit
inpati
may
also
candid
exclus
oral
treatment
hospit
patient
sequenti
treatment
consid
patient
except
sever
ill
optim
time
switch
oral
treatment
also
unknown
decis
guid
resolut
promin
clinic
featur
admiss
patient
probabl
necessari
observ
patient
hospit
switch
oral
treatment
switch
oral
treatment
reach
clinic
stabil
also
safe
patient
sever
pneumonia
efficaci
safeti
earli
switch
therapi
confirm
sever
studi
metaanalys
hospit
patient
nonsever
pneumonia
sepsi
reason
impair
intestin
absorpt
candid
oral
treatment
begin
switch
therapi
safe
may
guid
algorithm
pathway
routin
practic
inhospit
observ
switch
iv
oral
antibiot
patient
cap
may
avoid
also
patient
sever
pneumonia
switch
oral
antimicrobi
treatment
day
intraven
treatment
treatment
respons
safe
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
refer
object
design
evid
athanassa
et
al
earli
switch
oral
treatment
patient
moder
sever
communityacquir
pneumonia
metaanalysi
lee
lindstrom
earli
switch
oral
antibiot
earli
discharg
guidelin
manag
communityacquir
pneumonia
marra
et
al
efficaci
exclus
oral
antibiot
therapi
patient
hospit
nonsever
communityacquir
pneumonia
retrospect
studi
metaanalysi
nathan
et
al
inhospit
observ
antibiot
switch
pneumonia
nation
evalu
treatment
sever
sepsi
septic
shock
confin
support
measur
steroid
recommend
treatment
pneumonia
earli
mobil
shown
associ
better
outcom
purpos
studi
earli
mobil
defin
movement
bed
chang
horizont
upright
posit
least
min
first
h
hospit
progress
movement
subsequ
day
hospit
sever
studi
indic
noninvas
ventil
niv
may
also
work
patient
pneumonia
particularli
patient
copd
noninvas
ventil
shown
reduc
intub
patient
ard
treat
case
may
feasibl
also
effect
donotintub
patient
therefor
may
option
even
palli
care
despit
one
promis
control
trial
two
metaanalys
show
present
steroid
recommend
treatment
patient
cap
one
metaanalysi
fail
find
effect
follow
intervent
activ
protein
c
noninvas
mechan
ventil
anticoagul
immunoglobulin
granulocytecolonystimul
factor
statin
probiot
chest
physiotherapi
antiplatelet
drug
overthecount
cough
medic
beta
agonist
inhal
nitric
oxid
angiotensinconvert
enzym
inhibitor
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
refer
object
design
evid
antonelli
et
al
multiplecentr
survey
use
clinic
practic
noninvas
ventil
firstlin
intervent
acut
respiratori
distress
syndrom
bulow
thorsag
noninvas
ventil
donotintub
patient
followup
prospect
consecut
cohort
studi
confalonieri
et
al
hydrocortison
infus
sever
communityacquir
pneumonia
preliminari
random
studi
rct
confalonieri
et
al
acut
respiratori
failur
patient
sever
communityacquir
pneumonia
prospect
random
evalu
noninvas
ventil
ferrer
et
al
noninvas
ventil
sever
hypoxaem
respiratori
failur
random
clinic
trial
gorman
et
al
corticosteroid
treatment
sever
communityacquir
pneumonia
mundi
et
al
earli
mobil
patient
hospit
communityacquir
pneumonia
role
corticosteroid
sever
communityacquir
pneumonia
systemat
review
siempo
et
al
adjunct
therapi
communityacquir
pneumonia
systemat
review
aspir
pneumonia
suspect
recommend
agre
definit
aspir
pneumonia
suspect
cap
either
follow
episod
wit
aspir
occur
presenc
risk
factor
aspir
includ
reduc
conscious
level
dysphagia
due
mechan
neurolog
upper
digest
tract
dysfunct
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
compar
featur
aspir
pneumonia
ap
aspir
pneumon
reza
et
al
compar
featur
ap
patient
longterm
care
facil
commun
teramoto
et
al
identifi
frequenc
aspir
pneumonia
hospit
adult
cap
pc
empir
antibiot
treatment
recommend
aspir
pneumonia
recommend
studi
mainli
clindamycin
vs
compar
antibiot
mainli
includ
small
number
patient
per
treatment
arm
reach
consist
conclus
regard
superior
one
antibiot
regim
anoth
one
larger
open
rct
clinic
respons
ident
treat
moxifloxacin
treat
ampicillinsulbactam
signific
differ
could
miss
due
lack
blind
target
recruit
achiev
recommend
base
knowledg
like
caus
pathogen
antibiot
regim
use
studi
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
repeat
daili
measur
psi
found
rise
psi
relat
mortal
one
studi
practic
routin
practic
number
studi
use
creactiv
protein
level
admiss
repeat
measur
admiss
admiss
admit
icu
predict
clinic
outcom
measur
crp
day
day
appear
use
failur
crp
fall
day
associ
fivefold
increas
mortal
ventil
complic
procalcitonin
may
also
use
suffici
studi
make
recommend
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
refer
object
design
evid
brun
et
al
studi
relat
day
crp
level
inappropri
antibiot
therapi
chalmer
et
al
studi
crp
sever
predictor
cap
pc
chen
et
al
assess
valu
repeat
psi
measur
mortal
predictor
coelho
et
al
studi
relationship
crp
clinic
cours
cap
icu
hohenth
et
al
studi
relationship
daili
crp
complic
cap
pc
menendez
et
al
studi
relationship
cytokin
treatment
failur
nonrespond
patient
assess
recommend
two
type
treatment
failur
nonrespond
pneumonia
slowli
resolv
pneumonia
differenti
nonrespond
pneumonia
occur
first
h
admiss
usual
due
antimicrobi
resist
unusu
virul
organ
host
defenc
defect
nonrespons
h
usual
due
complic
evalu
nonrespond
pneumonia
depend
clinic
condit
trial
differ
approach
nonrespond
patient
guid
recommend
unstabl
patient
full
reinvestig
follow
second
empir
antimicrobi
treatment
regimen
carri
latter
may
withheld
stabl
patient
slowli
resolv
pneumonia
reinvestig
accord
clinic
need
condit
patient
hisher
individu
risk
factor
hospit
patient
copd
exacerb
receiv
antibiot
recommend
fever
observ
exacerb
relationship
purul
bacteri
growth
confirm
one
studi
addit
bronchoscop
studi
found
refer
purul
patient
sensit
specif
predict
posit
valu
neg
predict
valu
detect
bacteria
protect
specimen
brush
bronchoscop
sampl
copd
hospit
patient
exacerb
howev
small
studi
found
weak
associ
sputum
purul
bacteri
load
bacteri
growth
later
studi
gram
stain
sputum
best
indic
bacteri
infect
randomizedcontrol
trial
need
clarifi
copd
exacerb
patient
requir
hospit
would
benefit
antibiot
biomark
procalcitonin
may
help
detect
exacerb
requir
antibiot
inform
avail
come
singlecentr
random
studi
one
casecontrol
studi
aecopd
virus
found
import
percentag
aecopd
patient
requir
hospit
one
studi
focus
mycoplasma
pneumonia
microorgan
involv
hospit
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
refer
object
design
evid
allegra
et
al
studi
relationship
object
purul
presenc
bacteria
lieberman
et
al
studi
frequenc
fever
exacerb
pc
rohd
et
al
case
control
studi
investig
role
differ
virus
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
lieberman
et
al
studi
role
mycoplasma
pneumonia
hospit
patient
aecopd
soler
et
al
studi
associ
purul
bacteri
bronchoscop
sampl
brussek
et
al
studi
associ
sputum
colour
sputum
bacteri
load
burley
et
al
studi
associ
symptom
gram
stain
sputum
bacteri
growth
stolz
et
al
studi
valu
procalcitonin
decreas
use
antibiot
exacerb
copd
stratif
patient
copd
exacerb
recommend
order
direct
treatment
recommend
new
inform
recommend
reword
chang
confirm
p
aeruginosa
associ
small
percentag
exacerb
need
hospit
p
aeruginosa
exacerb
seem
independ
bronchial
bacteri
load
p
aeruginosa
repres
isol
microorgan
episod
taiwan
isol
p
aeruginosa
associ
poorer
outcom
casecontrol
studi
isol
multidrugresist
microorgan
aecopd
includ
p
aeruginosa
associ
higher
mortal
evid
studi
bacteri
infect
copd
exacerb
patient
need
hospit
ko
et
al
studi
sputum
microbiolog
aecopd
rosel
et
al
studi
microbiolog
determin
aecopd
lin
et
al
studi
microbiolog
aecopd
montero
et
al
studi
associ
multiresist
p
aeruginosa
outcom
aecopd
risk
factor
p
aeruginosa
recommend
p
aeruginosa
consid
presenc
least
two
follow
one
studi
investig
risk
factor
p
aeruginosa
prior
use
antibiot
risk
factor
p
aeruginosa
infect
influenza
vaccin
protect
factor
know
neg
predict
valu
find
studi
patient
acut
exacerb
identifi
follow
variabl
independ
predictor
gramneg
bacilli
p
aeruginosa
infect
fev
predict
valu
system
steroid
use
prior
antibiot
therapi
within
preced
month
neg
predict
valu
rule
recent
studi
garcia
vidal
et
al
found
risk
factor
p
aeruginosa
initi
sputum
bode
index
admiss
previou
year
system
steroid
treatment
previou
isol
p
aeruginosa
howev
larg
retrospect
studi
p
aeruginosa
found
independ
sever
uncompl
aecopd
vs
complic
aecopd
vs
despit
fact
recommend
treat
pseudomona
aeruginosa
remain
unchang
guidelin
member
panel
disagre
cover
pseudomona
aeruginosa
initi
empir
treatment
patient
risk
rational
behind
disagr
lie
studi
consid
p
aeruginosa
colon
pathogen
evid
studi
risk
factor
bacteri
exacerb
lode
et
al
studi
risk
factor
bacteri
aetiolog
aecopd
pc
garciavid
et
al
studi
risk
factor
p
aeruginosa
isol
aecopd
kahn
et
al
studi
entri
microbiolog
criteria
antibiot
trial
aecopd
microbiolog
investig
recommend
hospit
patient
copd
exacerb
recommend
sputum
cultur
endotrach
aspir
mechan
ventil
patient
obtain
good
altern
bronchoscop
procedur
evalu
bacteri
burden
potenti
pathogen
microorgan
recommend
modifi
new
inform
pathogen
associ
copd
bacteri
isol
patient
copd
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
recent
shown
associ
approxim
exacerb
copd
case
h
influenza
clear
patient
colon
ident
strain
h
influenza
extend
period
time
despit
intermitt
cultur
neg
colon
h
influenza
strain
cours
lifetim
copd
patient
flora
associ
exacerb
chang
sever
case
fev
normal
gramneg
flora
includ
p
aeruginosa
becom
increasingli
import
associ
pathogen
acquisit
new
strain
p
aeruginosa
associ
exacerb
causal
relationship
infect
exacerb
copd
purul
sputum
almost
alway
associ
significantli
posit
cultur
causal
relationship
infect
exacerb
copd
establish
associ
two
strong
prospect
analysi
copd
patient
exacerb
requir
hospit
papi
et
al
show
frequenc
isol
sputum
bacteria
virus
much
higher
exacerb
stabl
period
eosinophilia
within
sputum
higher
viral
infect
furthermor
longitudin
studi
bacteri
load
sputum
amongst
patient
copd
fev
declin
mirror
increas
sputum
bacteri
load
recent
detail
longitudin
studi
found
quantit
count
establish
sputum
flora
greatli
chang
stabl
exacerb
period
copd
patient
sethi
et
al
demonstr
exacerb
copd
caus
h
influenza
specif
immun
respons
infect
strain
h
influenza
psi
sampl
increas
diagnost
yield
respiratori
tract
sampl
patient
cystic
fibrosi
psi
sampl
increas
cultur
yield
p
aeruginosa
regular
sputum
sampl
evid
oral
gemifloxacin
levofloxacin
h
day
may
use
effect
treat
aecopd
patient
requir
hospit
inform
come
two
random
clinic
trial
compar
two
quinolon
standard
treatment
day
hospit
nonhospit
patient
aecb
metaanalysi
random
controlledtri
includ
six
studi
hospit
aecopd
patient
compar
call
firstlin
amoxicillin
ampicillin
trimetroprimsulphamethoxazol
secondlin
antibiot
amoxicillinclavulan
acid
macrolid
secondor
thirdgener
cephalosporin
aecopd
show
firstlin
antibiot
associ
lower
treatment
success
compar
secondlin
antibiot
mainli
macrolid
amoxicillinclavulan
new
inform
recommend
chang
combin
ciprofloxacin
inhal
tobramycin
may
improv
microbiolog
clinic
outcom
howev
patient
treat
inhal
tobramycin
wheez
observ
prolong
antibiot
therapi
shown
small
benefit
modifi
outcom
purul
bronchiectasi
antibiot
recommend
exacerb
bronchiectasi
risk
p
aeruginosa
infect
consid
valid
risk
factor
avail
howev
risk
appear
relat
recent
antibiot
therapi
hospit
seriou
diseas
prior
isol
pseudomona
speci
recommend
new
inform
puls
studi
investig
whether
puls
therapi
moxifloxacin
everi
week
day
period
abl
prolong
time
next
exacerb
copd
patient
comparison
placebo
studi
neg
although
trend
patient
purul
sputum
show
prolong
time
next
acut
exacerb
recommend
chang
evid
role
prophylact
antibiot
therapi
patient
copd
bronchiectasi
copd
recommend
use
nebul
antibiot
intermitt
longterm
macrolid
therapi
recommend
copd
patient
gener
use
nebul
antibiot
prevent
lrti
studi
small
group
patient
copd
one
random
clinic
trial
investig
use
erythromycin
mgday
month
copd
patient
aim
reduc
moder
sever
exacerb
patient
total
outpati
includ
trial
male
current
smoker
mean
sd
age
year
fev
l
fev
predict
thirtyeight
patient
three
exacerb
year
recruit
differ
treatment
group
total
moder
sever
exacerb
occur
placebo
arm
ten
placebo
group
nine
macrolid
group
withdrew
gener
linear
model
show
rate
ratio
exacerb
macrolidetr
patient
compar
placebotr
patient
confid
interv
p
patient
shorterdur
exacerb
compar
placebo
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
seemung
et
al
studi
efficaci
ad
mg
erythromycin
exist
treatment
regimen
patient
copd
b
bronchiectasisnebul
antibiot
recommend
enough
evid
recommend
use
nebul
antibiot
tobramycin
noncfbronchiectasi
nebul
tobramycin
use
success
cystic
fibrosi
patient
noncfbronchiectasi
patient
small
studi
done
one
found
effect
one
found
decreas
hospit
admiss
clinic
improv
clear
evid
recommend
use
inhal
tobramycin
could
drawn
studi
evid
c
bronchiectasismacrolid
recommend
enough
evid
recommend
use
intermitt
longterm
macrolid
therapi
noncfbronchiectasi
gener
use
intermitt
macrolid
therapi
success
patient
cf
patient
follow
lung
transplant
number
studi
investig
noncfbronchiectasi
patient
low
besid
letter
case
report
small
studi
one
retrospect
studi
publish
studi
investig
prophylaxi
azithromycinweek
bronchiectasi
patient
reduct
acut
exacerb
observ
well
increas
fev
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
oral
mucolyt
use
prevent
lrti
recommend
patient
bronchiectasi
oral
mucolyt
use
prevent
lrti
prescript
oral
mucolyt
winter
month
consid
frequent
prolong
exacerb
repeatedli
admit
hospit
exacerb
copd
inhal
corticosteroid
ic
prescrib
although
shown
oral
mucolyt
prevent
acut
exacerb
patient
chronic
bronchiti
shown
substanc
prevent
infect
gener
popul
howev
evid
individu
frequent
prolong
exacerb
repeatedli
admit
hospit
exacerb
copd
inhal
corticosteroid
ic
prescrib
may
benefit
prescript
oral
mucolyt
winter
month
third
systemat
review
row
shown
least
effect
oral
mucolyt
select
patient
sever
copd
frequent
exacerb
ic
barrett
et
al
ecchinacea
common
cold
rct
mcelhaney
et
al
extract
root
north
american
ginseng
panax
quinquefolium
heimer
et
al
vitamin
c
prevent
common
cold
oral
care
nurs
home
recommend
intensifi
oral
care
nurs
home
resid
consid
prevent
measur
reduc
incid
pneumonia
risk
death
pneumonia
patient
sinc
last
version
recommend
one
metaanalysi
two
intervent
trial
investig
question
intensifi
oral
care
nurs
home
patient
relat
prevent
lrti
pneumonia
evid
studi
risk
death
pneumonia
relat
dental
statu
bassim
et
al
studi
risk
mortal
pneumonia
oral
hygien
care
commonli
use
medic
decreas
risk
lrti
cap
sinc
last
version
recommend
varieti
commonli
use
drug
investig
regard
potenti
decreas
risk
lrti
cap
drug
inhal
steroid
copd
patient
aceinhibitor
statin
gener
popul
inhal
steroid
copd
patient
inhal
steroid
might
decreas
risk
acut
exacerb
subgroup
copd
patient
decreas
risk
lrti
fact
seem
increas
risk
ltricap
copd
patient
statin
use
gener
popul
risk
cap
death
cap
use
statin
andor
ace
inhibitor
gener
popul
investig
regard
potenti
decreas
risk
cap
caprel
death
use
statin
andor
ace
inhibitor
might
decreas
risk
cap
caprel
death
gener
popul
mani
data
statin
ace
inhibitor
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
studi
mortal
pneumonia
current
statin
user
tleyjeh
et
al
studi
statin
use
prevent
infect
sr
influenza
vaccin
use
prevent
lrti
recommend
influenza
vaccin
given
yearli
person
increas
risk
complic
due
influenza
vaccin
given
immunocompet
adult
belong
one
follow
categori
age
year
institution
chronic
cardiac
diseas
chronic
pulmonari
diseas
diabet
mellitu
chronic
renal
diseas
haemoglobinopathi
women
second
third
trimest
pregnanc
influenza
season
elderli
year
age
highrisk
adult
irrespect
age
new
studi
confirm
season
influenza
vaccin
effect
prevent
sever
complic
death
due
influenza
result
base
noncontrol
studi
may
result
either
pessimist
optimist
view
effect
vaccin
latter
base
healthi
user
bias
shown
sever
recent
studi
recent
cochran
analysi
unabl
reach
clear
conclus
effect
influenza
vaccin
elderli
must
emphas
lack
evid
equal
lack
effect
far
unfortun
one
random
control
studi
high
qualiti
studi
clearli
demonstr
vaccin
effect
prevent
clinic
laboratori
verifi
influenza
elderli
power
detect
effect
complic
howev
base
studi
reason
assum
vaccin
also
prevent
sever
influenza
complic
accord
find
larg
major
wellperform
observ
studi
specif
agelimit
year
age
recommend
gener
season
influenza
vaccin
use
guidelin
base
fact
trial
use
cutoff
inclus
patient
andor
analysi
result
countri
gener
vaccin
recommend
also
age
group
year
eg
usa
vaccin
recommend
person
age
year
person
age
group
increas
preval
highrisk
condit
low
vaccin
rate
yearli
vaccin
season
influenza
vaccin
lead
decreas
immun
respons
protect
frequent
effect
seen
primari
vaccin
two
new
studi
confirm
inactiv
inject
influenza
vaccin
superior
live
attenu
vaccin
healthi
adult
howev
although
season
influenza
vaccin
prevent
respiratori
ill
healthi
adult
revis
cochran
analysi
demich
et
al
indic
vaccin
limit
clinic
valu
group
patient
systemat
review
indic
vaccin
health
care
personnel
influenza
may
reduc
influenzalik
ill
allcaus
mortal
elderli
peopl
longterm
hospit
demonstr
effect
specif
outcom
laboratoryproven
influenza
pneumonia
death
pneumonia
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
studi
effect
influenza
vaccin
adult
copd
jackson
et
al
studi
effect
influenza
vaccin
elderli
person
thoma
et
al
studi
effect
influenza
vaccin
healthcar
worker
order
protect
elderli
person
sr
squarcion
et
al
studi
immunogen
reactogen
inactiv
influenza
vaccin
older
person
rct
wang
et
al
studi
live
attenu
vs
inactiv
influenza
vaccin
medic
encount
respiratori
ill
among
us
militari
personnel
monto
et
al
compar
efficaci
inactiv
live
attenu
influenza
vaccin
healthi
adult
nichol
et
al
studi
effect
influenza
vaccin
prevent
influenzalik
ill
schembri
et
al
studi
effect
influenza
vaccin
prevent
allcaus
mortal
elderli
person
rtqvist
et
al
studi
effect
influenza
vaccin
prevent
allcaus
mortal
elderli
person
eurich
et
al
studi
effect
influenza
vaccin
prevent
allcaus
mortal
elderli
person
jackson
et
al
studi
effect
influenza
vaccin
prevent
communityacquir
pneumonia
immunocompet
elderli
peopl
jefferson
et
al
studi
vaccin
prevent
influenza
elderli
sr
thoma
et
al
studi
effect
influenza
vaccin
healthcar
worker
work
elderli
pneumococc
vaccin
use
prevent
lrti
recommend
polysaccharid
pneumococc
vaccin
prevent
invas
pneumococc
diseas
older
person
highrisk
group
given
adult
person
risk
pneumococc
diseas
risk
factor
pneumococc
diseas
age
year
institution
dementia
seizur
disord
congest
heart
failur
cerebrovascular
diseas
chronic
obstruct
pulmonari
diseas
histori
previou
pneumonia
chronic
liver
diseas
diabet
mellitu
function
anatom
asplenia
chronic
cerebrospin
fluid
leakag
although
smoke
seem
signific
risk
factor
otherwis
healthi
younger
adult
measur
aim
reduc
smoke
exposur
environment
tobacco
smoke
prefer
group
revaccin
earlier
year
primari
vaccin
perform
asplen
patient
consid
elderli
highrisk
group
enough
data
give
recommend
concern
use
conjug
pneumococc
vaccin
adult
immunogen
polysaccharid
pneumococc
vaccin
ppv
gener
good
may
poor
elderli
patient
person
underli
ill
eg
bronchiectasi
also
import
stress
ppv
includ
antigen
person
develop
pneumococc
diseas
one
serotyp
despit
respond
other
previous
conflict
data
concern
whether
pneumococc
conjug
vaccin
pcv
could
result
superior
immun
respons
elderli
patient
highrisk
adult
compar
ppv
coupl
recent
studi
indic
may
case
drawback
pcv
howev
limit
number
serotyp
much
higher
price
lack
data
efficaci
although
larg
rct
underway
vaccin
children
pcv
may
benefit
also
adult
sinc
start
vaccin
children
pcv
usa
mark
reduct
ipd
note
vaccin
cohort
adult
herd
immun
effect
mark
age
group
parent
year
age
grandpar
year
age
concern
outcom
herd
effect
less
clear
one
studi
indic
decreas
allcaus
pneumonia
pneumococc
pneumonia
adult
year
age
anoth
show
impact
allcaus
pneumonia
adult
efficaci
ppv
adult
includ
elderli
evalu
eight
metaanalysessystemat
review
masr
random
control
trial
rct
three
recent
review
also
includ
systemat
review
observ
studi
invas
pneumococc
diseas
ipd
last
year
one
doubleblind
random
control
trial
studi
effect
ppv
publish
masr
rct
shown
strong
evid
ppv
efficaci
prevent
invas
pneumococc
diseas
ipd
healthi
adult
includ
elderli
protect
efficaci
effect
ipd
may
somewhat
poorer
person
chronic
ill
estim
protect
ipd
sr
observ
studi
consist
homogen
compat
rct
report
signific
reduct
incid
ipd
elderli
introduct
largescal
vaccin
programm
two
european
countri
support
effect
vaccin
ipd
limit
evid
ppv
prevent
allcaus
pneumonia
elderli
risk
group
howev
recent
doubleblind
random
control
trial
among
nurs
home
resid
japan
demonstr
ppv
associ
reduct
incid
allcaus
pneumonia
pneumococc
pneumonia
also
signific
higher
death
rate
among
person
pneumococc
pneumonia
placebo
group
vs
studi
support
earlier
find
recent
cohort
studi
indic
ppv
associ
reduct
pneumonia
overal
pneumococc
pneumonia
hospit
pneumonia
death
due
pneumonia
contrast
cohort
studi
found
protect
allcaus
pneumonia
hospit
pneumonia
open
rct
perform
adult
copd
high
degre
protect
cap
due
pneumonia
unknown
aetiolog
seen
person
year
age
especi
sever
function
obstruct
fev
contrast
pneumococc
vaccin
alter
significantli
risk
overal
cap
cohort
studi
older
adult
chronic
respiratori
diseas
european
studi
vaccin
ppv
elderli
costsav
shown
moder
good
costeffect
prevent
hospit
admiss
ipd
recent
studi
indic
pneumoccooc
vaccin
would
cost
neutral
efficaci
ipd
pneumococc
pneumonia
elderli
vaccin
efficaci
ipd
net
cost
societi
would
per
year
life
save
use
data
effect
herd
immun
usa
estim
would
costeffect
adult
point
view
vaccin
children
uk
four
dose
sevenval
conjug
vaccin
safeti
immunogen
one
revaccin
pneumococc
vaccin
confirm
sever
studi
larg
random
control
trial
patient
previous
receiv
one
dose
ppv
random
receiv
ppv
pcv
four
differ
dosag
local
sideeffect
common
usual
mild
frequenc
local
reaction
pcv
group
depend
dose
given
highest
dosag
group
risk
reaction
compar
ppv
prospect
cohort
studi
elderli
person
median
age
year
revaccin
averag
year
primari
vaccin
signific
increas
geometr
mean
antibodi
concentr
geometr
mean
antibodi
fold
increas
seen
although
lower
level
primari
vaccin
thirtysix
patient
respond
fold
increas
two
six
serotyp
earli
revaccin
may
lead
shortliv
antibodi
rise
could
due
immunolog
suppress
toler
howev
suppress
effect
seem
wane
year
studi
revaccin
perform
year
person
respond
well
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
compar
immunogen
ppv
pcv
healthi
highrisk
adult
sr
kyaw
et
al
studi
effect
reduc
ipd
adult
vaccin
children
conjug
pneumococc
vaccin
whitney
et
al
studi
effect
reduc
ipd
adult
vaccin
children
conjug
pneumococc
vaccin
melegaro
edmund
studi
efficaci
ppv
adult
year
age
sr
dear
et
al
studi
efficaci
ppv
adult
sr
conati
et
al
studi
efficaci
ppv
adult
sr
alfagem
et
al
studi
efficaci
ppv
adult
copd
jackson
et
al
studi
efficaci
ppv
adult
year
age
christenson
et
al
studi
efficaci
ppv
adult
year
age
pc
rcole
et
al
studi
efficaci
ppv
adult
year
age
fisman
et
al
studi
efficaci
ppv
adult
rc
mykietiuk
et
al
studi
efficaci
ppv
adult
pc
melegaro
et
al
studi
costeffect
ppv
elderli
person
mangtani
et
al
studi
costeffect
ppv
elderli
person
mcintosh
et
al
studi
costeffect
adult
vaccin
children
pcv
jackson
et
al
compar
safeti
ppv
pcv
elderli
person
et
al
studi
immun
respons
revaccin
ppv
elderli
person
sisk
studi
costeffect
ppv
adult
year
age
andrew
studi
efficaci
ppv
adult
year
age
pepper
studi
costeffect
ppv
healthi
adult
ortqvist
et
al
studi
respons
specif
serotyp
caus
failur
pneumococc
polysaccharid
vaccin
elderli
musher
et
al
studi
initi
subsequ
respons
pneumococc
polysaccharid
proteinconjug
vaccin
administ
sequenti
adult
recov
pneumococc
pneumonia
pc
de
roux
et
al
compar
pneumococc
conjug
polysaccharid
free
polysaccharid
vaccin
elderli
adult
grijalva
et
al
studi
pneumonia
admiss
routin
childhood
immun
pneumococc
conjug
vaccin
usa
nelson
et
al
studi
impact
introduct
pneumococc
conjug
vaccin
rate
communityacquir
pneumonia
children
adult
moberley
et
al
systemat
review
vaccin
prevent
pneumococc
infect
adult
sr
maruyama
et
al
studi
efficaci
pneumococc
vaccin
prevent
pneumonia
improv
surviv
nurs
home
resid
christenson
et
al
studi
effect
influenza
pneumococc
vaccin
elderli
peopl
ochoagondar
et
al
studi
effect
pneumococc
vaccin
older
adult
chronic
respiratori
diseas
pc
lee
et
al
studi
impact
pneumococc
vaccin
pneumonia
rate
adult
patient
copd
asthma
skull
et
al
studi
whether
influenza
andor
pneumococc
vaccin
prevent
hospit
communityacquir
pneumonia
elderli
cc
johnston
et
al
studi
effect
pneumococc
vaccin
hospit
adult
communityacquir
pneumonia
wait
et
al
studi
effect
revaccin
adult
spinal
cord
injuri
use
pneumococc
polysaccharid
vaccin
recommend
activ
intervent
use
enhanc
vaccin
either
vaccin
effect
need
order
achiev
adequ
vaccin
coverag
target
popul
new
studi
confirm
differ
type
intervent
eg
patient
remind
stand
order
effect
increas
vaccin
target
popul
influenza
pneumococc
diseas
evid
tabl
metaanalysi
systemat
review
rct
random
control
trial
pc
prospect
cohort
studi
rc
retrospect
cohort
studi
cc
casecontrol
studi
css
crosssect
studi
sr
systemat
review
systemat
review
metaanalys
studi
type
grade
random
trial
prospect
cohort
casecontrol
crosssect
retrospect
cohort
case
report
expert
opinion
consensu
